Literature DB >> 30605703

Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.

Tovi Shapira-Furman1, Riccardo Serra2, Noah Gorelick2, Marisol Doglioli2, Valentina Tagliaferri2, Arba Cecia2, Michael Peters2, Awanish Kumar1, Yakir Rottenberg3, Robert Langer4, Henry Brem5, Betty Tyler6, Abraham J Domb7.   

Abstract

Glioblastoma multiforme (GBM) has few clinically approved therapeutic regimens. One of these therapeutic options includes placing biodegradable wafers releasing BCNU (Gliadel®) into the tumor bed at the time of surgical removal of the tumor. Due to the significant benefit this polymer technology has had clinically, we have prepared wafers releasing Temozolomide (TMZ), an anticancer drug used systemically for treating GBM. TMZ delivered via polymer wafer could be used as a complementary treatment with or as an alternative to Gliadel®. TMZ is an alkylating agent which is water soluble. To remain comparable with the preclinical studies that led to Gliadel® the same size of wafers were formulated with TMZ. Wafers were loaded with 50% w/w TMZ in poly(lactic acid-glycolic acid) (PLGA) and showed reliable release of high dose TMZ for a period of 4 weeks. To achieve this 30-day release of the highly water soluble drug, we developed an encapsulation method, where the drug powder was first coated with the polymer to form core-shell particles in which the coating shell served as a rate controlling membrane for the drug particles. Wafers were also made with a co-loading of TMZ and BCNU. All wafers were tested in vivo by treating an intracranial 9 L gliosarcoma model in F344 rats. Rats that were either untreated or treated with blank wafer died within 11 days while the median survival for rats treated with systemic TMZ was 18 days. The group that received the BCNU alone wafer had a median survival of 15 days, the group that received the TMZ wafer alone had a median survival of 19 days, and the group treated with the BCNU-TMZ wafer had a median survival of 28 days with 25% of the animals living long term (p < .0038 vs. Control; p < .001 vs. Blank Polymer). These findings demonstrate the potential of this newly designed wafer for treating GBM. Moreover, this concept, can pave the way for other drug combinations that may improve the clinical application of numerous agents to treat solid tumors.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BCNU; Brain tumor; GBM; Gliadel; PLGA; Temozolomide (TMZ)

Mesh:

Substances:

Year:  2018        PMID: 30605703     DOI: 10.1016/j.jconrel.2018.12.048

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  19 in total

Review 1.  Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment.

Authors:  Wiam El Kheir; Bernard Marcos; Nick Virgilio; Benoit Paquette; Nathalie Faucheux; Marc-Antoine Lauzon
Journal:  Pharmaceutics       Date:  2022-06-01       Impact factor: 6.525

Review 2.  Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy.

Authors:  Dannielle H Upton; Caitlin Ung; Sandra M George; Maria Tsoli; Maria Kavallaris; David S Ziegler
Journal:  Theranostics       Date:  2022-06-06       Impact factor: 11.600

Review 3.  Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.

Authors:  Yuzhe Sun; Edward Davis
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

4.  Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.

Authors:  Elizabeth G Graham-Gurysh; Ananya B Murthy; Kathryn M Moore; Shawn D Hingtgen; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2020-04-23       Impact factor: 9.776

5.  Neuroinflammation After Stereotactic Radiosurgery-Induced Brain Tumor Disintegration Is Linked to Persistent Cognitive Decline in a Mouse Model of Metastatic Disease.

Authors:  Chengyan Chu; Catherine M Davis; Xiaoyan Lan; Robert D Hienz; Anna Jablonska; Aline M Thomas; Esteban Velarde; Shen Li; Miroslaw Janowski; Mihoko Kai; Piotr Walczak
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-05-26       Impact factor: 7.038

Review 6.  Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology.

Authors:  Andrew M Hersh; Safwan Alomari; Betty M Tyler
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

Review 7.  Evolution of drug-eluting biomedical implants for sustained drug delivery.

Authors:  Juliana C Quarterman; Sean M Geary; Aliasger K Salem
Journal:  Eur J Pharm Biopharm       Date:  2020-12-16       Impact factor: 5.589

Review 8.  Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.

Authors:  Stephanie Sanders; Waldemar Debinski
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

9.  Patents and Innovation Among Neurosurgeons from the American Association of Neurological Surgeons.

Authors:  Rebecca B Baron; Remi A Kessler; Ansh Bhammar; Nicholas Boulis; John R Adler; Karan Kohli; Constantinos Hadjipanayis
Journal:  Cureus       Date:  2020-02-18

10.  Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.

Authors:  Guangwei Zhu; Ming Zhao; Qinghong Han; Yuying Tan; Yu Sun; Michael Bouvet; Bryan Clary; Shree Ram Singh; Jianxin Ye; Robert M Hoffman
Journal:  Transl Oncol       Date:  2020-03-03       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.